Harry’s guest for this unusually frank and urgent episode is Jacob Glanville, the founding partner, CEO, and president of Distributed Bio. The company is using its skills in computational antibody analysis and optimization to help the drug industry develop new vaccines and antibody-based treatments for a range of diseases, potentially including the coronavirus that causes COVID-19.
The content above was previously recorded. The views herein were made at the time of this recording and are not updated to reflect changes in economic or financial circumstances. The opinions are those of the contributor and not Scientia Ventures, LLC, its affiliates, officers, or employees. Nothing herein constitutes a recommendation, solicitation, or offer to purchase securities or private funds, which can only be made through the relevant offering documents.
